Meeting with ChiaTai TianQing Pharmaceutical Group (正大天晴藥業集團交流會)

HKUMed and ChiaTai TianQing Pharmaceutical Group Explore New Opportunities in Medical Innovation
—2025 Nanjing Symposium Focuses on Research Translation and Industry Collaboration

Nanjing, April 27, 2025—The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and Chia Tai Tianqing Pharmaceutical Group (CTTQ) convened a high-level symposium today in Nanjing to strengthen collaboration in medical innovation. The event, led by HKUMed Dean Professor CS LAU, included key representatives such as Associate Dean (Research) Professor Eric TSE, Executive Director of the Greater Bay Area International Clinical Trials Institute Professor Bernard CHEUNG, Director of the Centre for Translational Stem Cell Biology Professor Pengtao LIU, and Head of Technology Transfer Unit Dr. Kenneth LAI. CTTQ’s delegation was headed by three Vice Presidents—Mr. Hui CHEN, Mr. Wei ZHAO, and Ms. Ling YANG—alongside senior leaders from their R&D and clinical divisions.

The discussions centered on advancing pharmaceutical R&D, technology transfer, and clinical application strategies. Delegates toured CTTQ’s R&D and production headquarters, underscoring the shared goal of bridging academic research with industrial innovation to establish a strategic partnership platform for innovative drug development and global health initiatives.

About Chia Tai Tianqing Pharmaceutical Group
Chia Tai Tianqing is a top-tier Chinese pharmaceutical enterprise specializing in innovative drug development and production for liver diseases, oncology, respiratory disorders, and other critical therapeutic areas. Its products reach over 30 countries and regions worldwide.

This event highlights HKUMed’s commitment to fostering industry-academia partnerships that translate cutting-edge research into real-world health solutions.

香港大學與正大天晴藥業集團共商醫藥創新合作新機遇
——2025年南京交流會聚焦科研轉化與產業協同發展

南京，2025年4月27日——香港大學醫學院與正大天晴藥業集團於今日在南京舉行高層交流會，此次會議由香港大學醫學院院長劉澤星教授率團參與，同行成員包括副院長（研究）謝偉財教授, 粵港澳大灣區國際臨床試驗所行政總裁張文勇教授, 幹細胞轉化研究中心總監劉澎濤教授 及 技術轉移部主管賴景然博士；正大天晴藥業集團則由三名副總裁陳輝先生, 趙偉先生及楊玲女士率領研究及臨床中心等高層代表接待。雙方圍繞醫藥研發、技術轉化及臨床應用等領域展開深入探討，並參觀了正大天晴藥業集團的研發及生產基地總部，旨在推動學術研究與產業實踐的深度融合，共築創新藥物研發與全球健康事業的戰略合作平台。

關於正大天晴藥業集團
正大天晴為中國領先的醫藥企業，專注於肝病、腫瘤、呼吸系統疾病等領域的創新藥物研發與生產，業務遍及全球30餘個國家及地區。